A Phase III Trial of Carboplatin as Adjuvant Chemotherapy in Triple Negative Breast Cancer
Status:
Unknown status
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
This study is designed to investigate the efficacy of carboplatin, as a post-operative
adjuvant chemotherapy for triple negative breast cancer patients who have pathologic residual
cancer after the preoperative chemotherapy.